Alembic Pharmaceuticals to attend Trinity India 2026 conference

0 min read Updated on 25 May 2026, 11:05 AM

Reviewed by

Jubin VScanX News Team

AI Summary

Alembic Pharmaceuticals Limited will participate in the Trinity India 2026 conference in Mumbai on May 29, 2026, hosted by B&K Securities. The company will hold meetings with institutional investors on a one-to-one and group basis. No unpublished price sensitive information will be disclosed during these sessions.

*this image is generated using AI for illustrative purposes only.

alembic pharmaceuticals has announced its participation in the 16th Annual Global Investor Conference, titled Trinity India 2026. The event is being hosted by B&K Securities and is scheduled to be held in Mumbai on May 29, 2026. The intimation was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the conference, the company plans to conduct physical meetings with institutional investors. These interactions will occur on both a one-to-one basis and in group settings. The purpose of these meetings is to engage with investors and discuss the company's performance and outlook.

The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the course of these meetings. This disclosure ensures compliance with regulatory standards regarding the sharing of material non-public information.

The communication was addressed to the stock exchanges, including BSE Limited and the National Stock Exchange of India Ltd, to keep the information on record. The notification was signed by G. Krishnan, the Chief Financial Officer of the company.

Historical Stock Returns for Alembic Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.87%	-2.78%	-0.30%	-15.39%	-21.51%	-20.62%

What key financial metrics or strategic initiatives is Alembic Pharmaceuticals likely to highlight to attract institutional investor interest at the Trinity India 2026 conference?

How might increased institutional investor engagement following this conference impact Alembic Pharmaceuticals' stock liquidity and foreign institutional ownership patterns?

What pipeline developments or expansion plans in the US generics or domestic formulations market could Alembic Pharmaceuticals discuss to strengthen investor confidence?

USFDA Approval Details

The final approval covers Levothyroxine Sodium Tablets USP in strengths of 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Levothyroxine sodium is indicated as a replacement or adjunct therapy for various forms of hypothyroidism and thyroid cancer.

Parameter	Details
Product	Levothyroxine Sodium Tablets USP
Strengths	25 mcg to 300 mcg
Reference Listed Drug	Synthroid Tablets (AbbVie Inc.)
Approval Type	USFDA Final Approval

Market Opportunity

According to IQVIA data, Levothyroxine Sodium Tablets USP have an estimated market size of US$ 1,869 million for the twelve months ending March 2026. This approval allows Alembic Pharmaceuticals to commercialize a product with significant demand in the US market.

Alembic Pharmaceuticals now holds a cumulative total of 239 ANDA approvals from the USFDA, comprising 220 final approvals and 19 tentative approvals.

Historical Stock Returns for Alembic Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.87%	-2.78%	-0.30%	-15.39%	-21.51%	-20.62%

How will Alembic Pharmaceuticals price its Levothyroxine Sodium Tablets to compete against established generic players already present in the $1.87 billion US market?

Could this approval accelerate Alembic's plans to expand its US generics portfolio, and are there other high-value thyroid or endocrinology drugs in their pipeline?

How might AbbVie respond to increased generic competition for Synthroid, and what impact could this have on its branded drug revenues?